Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Industry Should Accept Small NHI Price Cuts Not Based on Market Prices: Mr Futagawa
March 13, 2006
- 6.7% Cut Equivalent to Loss of \400 Bil. in Profits: Mr Mukaida
March 13, 2006
- Bulk Buying Accounts for 45.1% of Total Sales: FJPWA Survey
March 13, 2006
- Proposed Policy on Return of Goods Approved by Ryukaikon
March 13, 2006
- Korosho Wants to See All Original Brands Available at the Same Strengths
March 13, 2006
- REGULATORY NEWS IN BRIEF
March 13, 2006
- Hayashibara to Develop Alzheimer's Disease Vaccine
March 13, 2006
- Bayer Yakuhin to Create Anticancer Drug Division
March 6, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 6, 2006
- Femara to Drive Growth of Novartis Pharma
March 6, 2006
- STATSUTICS
March 6, 2006
- MediciNova to Out-license 1st Product This Year: Dr Iwaki
March 6, 2006
- BUSINESS NEWS IN BRIEF
March 6, 2006
- Bill to Amend PAL to Be Presented to Diet on March 10
March 6, 2006
- DSP's Ambisome to Be Approved for Import
March 6, 2006
- Astellas' Vesicare Recommended for Approval: CDFS
March 6, 2006
- Korosho to Move to Eliminate Provisional Delivery of Drugs
March 6, 2006
- REGULATORY NEWS IN BRIEF
March 6, 2006
- Bayer, Onyx Initiate PIII Lung Cancer Study Using Nexavar
March 6, 2006
- SEMIANAR
March 6, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…